{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:28:53Z","timestamp":1782275333616,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10067-018-4043-0","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T01:59:24Z","timestamp":1519264764000},"page":"1249-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The safety of iloprost in systemic sclerosis in a real-life experience"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-6263","authenticated-orcid":false,"given":"S.","family":"Bellando-Randone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ML","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moggi-Pignone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Giuggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"4043_CR1","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953\u20131962","journal-title":"Arthritis Rheum"},{"key":"4043_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3899\/jrheum.111380","volume":"39","author":"TM Frech","year":"2012","unstructured":"Frech TM, Revelo MP, Drakos SG, Murtaugh MA, Markewitz BA, Sawitzke AD et al (2012) Vascular leak is a central feature in the pathogenesis of systemic sclerosis. J Rheumatol 39:1385\u20131391","journal-title":"J Rheumatol"},{"issue":"19","key":"4043_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-017-1370-5","volume":"6","author":"M Matucci-Cerinic","year":"2017","unstructured":"Matucci-Cerinic M, Manetti M, Bruni C, Chora I, Bellando Randone S, Lepri G et al (2017) The \u201cmyth\u201d of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? Arthritis Res Ther 6(19):162","journal-title":"Arthritis Res Ther"},{"key":"4043_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11926-011-0219-1","volume":"14","author":"BJ Rabquer","year":"2012","unstructured":"Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14:56\u201363","journal-title":"Curr Rheumatol Rep"},{"key":"4043_CR5","first-page":"CD002069","volume":"2","author":"H Ennis","year":"2016","unstructured":"Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick A (2016) Calcium channel blockers for primary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev 2:CD002069","journal-title":"Cochrane Database Syst Rev"},{"key":"4043_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.30195","volume":"63","author":"AL Herrick","year":"2011","unstructured":"Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, V\u00e1zquez-Abad MD, Denton CP (2011) Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63:775\u2013782","journal-title":"Arthritis Rheum"},{"key":"4043_CR7","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"AE Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841\u20131847","journal-title":"Arthritis Rheum"},{"key":"4043_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/ard.2007.073684","volume":"66","author":"ME Hettema","year":"2007","unstructured":"Hettema ME, Zhang D, Bootsma H, Kallenberg CGM (2007) Bosentan therapy for patients with severe Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis 66:1398\u20131399","journal-title":"Ann Rheum Dis"},{"key":"4043_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"4043_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/03009742.2011.569755","volume":"40","author":"A Della Rossa","year":"2011","unstructured":"Della Rossa A, Doveri M, D\u2019Ascanio A, Tavoni A, Consensi A, Neri R et al (2011) Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol 40:323\u2013325","journal-title":"Scand J Rheumatol"},{"key":"4043_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I, Czirjal L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"4043_CR12","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1002\/art.20665","volume":"50","author":"RA Wise","year":"2004","unstructured":"Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994\u20134001","journal-title":"Arthritis Rheum"},{"key":"4043_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00296-015-3241-1","volume":"35","author":"P Garc\u00eda de la Pe\u00f1a Lefebvre","year":"2015","unstructured":"Garc\u00eda de la Pe\u00f1a Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Rom\u00e1n Ivorra JA, Carreira P, R\u00faa-Figueroa I, Pego-Reigosa JM, Mu\u00f1oz-Fern\u00e1ndez S (2015) Efficacy of Raynaud\u2019s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int 35:1447\u20131459","journal-title":"Rheumatol Int"},{"key":"4043_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","volume":"120","author":"FM Wigley","year":"1994","unstructured":"Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199\u2013206","journal-title":"Ann Intern Med"},{"key":"4043_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1096\/fj.02-0204fje","volume":"16","author":"R Stratton","year":"2002","unstructured":"Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM et al (2002) Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras\/MEK\/ERK pathway. FASEB J 16:1949\u20131951","journal-title":"FASEB J"},{"issue":"108","key":"4043_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI12020","volume":"2001","author":"R Stratton","year":"2001","unstructured":"Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001(108):241\u2013250","journal-title":"J Clin Invest"},{"issue":"1","key":"4043_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00395-003-0383-1","volume":"98","author":"S Lindemann","year":"2003","unstructured":"Lindemann S, Gierer C, Darius H (2003) Prostacyclin inhibits adhesion of polymorphonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol 98(1):8\u201315","journal-title":"Basic Res Cardiol"},{"key":"4043_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0140-6736(90)90346-7","volume":"335","author":"JN Fiessinger","year":"1990","unstructured":"Fiessinger JN, Sch\u00e4fer M (1990) Trial of iloprost versus aspirin treatment for critical limb ischemia for thromboangiitis obliterans. Lancet 335:555\u2013557","journal-title":"Lancet"},{"key":"4043_CR19","first-page":"1407","volume":"19","author":"FM Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19:1407\u20131414","journal-title":"J Rheumatol"},{"key":"4043_CR20","first-page":"503","volume":"19","author":"R Scorza","year":"2001","unstructured":"Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503\u2013508","journal-title":"Clin Exp Rheumatol"},{"key":"4043_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02214941","volume":"14","author":"DJ Veale","year":"1995","unstructured":"Veale DJ, Muir AH, Morley KD, Belch JJF (1995) Treatment of vasculitic leg ulcers in connective tissue disease with iloprost. Clin Rheumatol 14:187\u2013191","journal-title":"Clin Rheumatol"},{"key":"4043_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/0140-6736(93)92719-A","volume":"342","author":"J Zahavi","year":"1993","unstructured":"Zahavi J, Charach G, Schafer R, Toeg A, Zahavi M (1993) Ischaemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet 342:862","journal-title":"Lancet"},{"key":"4043_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/ard.54.3.197","volume":"54","author":"JJ Belch","year":"1995","unstructured":"Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, Murphy E, Steinberg M (1995) Oral iloprost as a treatment for Raynaud\u2019s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54:197\u2013200","journal-title":"Ann Rheum Dis"},{"key":"4043_CR24","first-page":"1403","volume":"19","author":"MV Kyle","year":"1992","unstructured":"Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud\u2019s phenomenon. J Rheumatol 19:1403\u20131406","journal-title":"J Rheumatol"},{"key":"4043_CR25","first-page":"35","volume":"11","author":"CS Lau","year":"1993","unstructured":"Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, Thompson JM (1993) A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud\u2019s phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 11:35\u201340","journal-title":"Clin Exp Rheumatol"},{"key":"4043_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.47.1.43","volume":"47","author":"NJ McHugh","year":"1988","unstructured":"McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF et al (1988) Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis 47:43\u201347","journal-title":"Ann Rheum Dis"},{"key":"4043_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/rheumatology\/27.3.220","volume":"27","author":"DA Yardumian","year":"1988","unstructured":"Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM et al (1988) Successful treatment of Raynaud\u2019s syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 27:220\u2013226","journal-title":"Br J Rheumatol"},{"key":"4043_CR28","first-page":"CD000953","volume":"2","author":"J Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2:CD000953","journal-title":"Cochrane Database Syst Rev."},{"key":"4043_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"M Rademaker","year":"1989","unstructured":"Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 298:561\u2013564","journal-title":"Br Med J"},{"key":"4043_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","volume":"45","author":"G Milio","year":"2006","unstructured":"Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S (2006) Iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 45:999\u20131004","journal-title":"Rheumatology"},{"key":"4043_CR31","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen Van den","year":"2013","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"4043_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/PL00011223","volume":"21","author":"L Bettoni","year":"2002","unstructured":"Bettoni L, Geri A, Air\u00f2 P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244\u2013250","journal-title":"Clin Rheumatol"},{"key":"4043_CR33","first-page":"13","volume":"20","author":"G Bali","year":"2011","unstructured":"Bali G, Schwantzer G, Aberer F, Kraenke B, Aberer E (2011) Discontinuing long-term iloprost treatment for Raynaud\u2019s phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study. Acta Dermatovenerol Alp Pannonica Adriat 20:13\u201321","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"4043_CR34","first-page":"179","volume":"106","author":"M Colaci","year":"2017","unstructured":"Colaci M, Lumetti F, Giuggioli D, Guiducci S, Bellando-Randone S, Fiori G et al (2017) Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. Clin Exp Rheumatol 106:179\u2013183","journal-title":"Clin Exp Rheumatol"},{"key":"4043_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2013-203889","volume":"74","author":"G Lepri","year":"2015","unstructured":"Lepri G, Bellando-Randone S, Guiducci S, Giani I, Bruni C, Blagojevic J et al (2015) Esophageal and anorectal involvement in patients with very early diagnosis of systemic sclerosis (VEDOSS): report from a single EUSTAR centre. Ann Rheum Dis 74:124\u2013128","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4043_CR36","first-page":"333","volume":"26","author":"M Colaci","year":"2008","unstructured":"Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Rossi R, Modena MG, Ferri C (2008) Cardiovascular risk and prostanoids in systemic sclerosis. Clin Exp Rheumatol 26(2):333\u2013336","journal-title":"Clin Exp Rheumatol"},{"key":"4043_CR37","first-page":"140","volume":"53","author":"M Arreghini","year":"2001","unstructured":"Arreghini M, Prudente P, Maglione W, Arnoldi C, Tosi S, Marchesoni A (2001) Tolerability, safety and efficacy of iloprost infusion without peristaltic pump in systemic sclerosis. Reumatismo 53:140\u2013144","journal-title":"Reumatismo"},{"key":"4043_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/ard.50.11.800","volume":"50","author":"HI Torley","year":"1991","unstructured":"Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, Englert H, Dormandy JA, Watson HR (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud\u2019s phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50:800\u2013804","journal-title":"Ann Rheum Dis"},{"key":"4043_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10067-009-1155-6","volume":"28","author":"P Caramaschi","year":"2009","unstructured":"Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, Mahamid H, Bambara LM, Biasi D (2009) A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 28:807\u2013813","journal-title":"Clin Rheumatol"},{"key":"4043_CR40","first-page":"1830","volume":"35","author":"A Kawald","year":"2008","unstructured":"Kawald A, Burmester GR, Huscher D, Sunderk\u00f6tter C, Riemekasten G (2008) Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud\u2019s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 35:1830\u20131837","journal-title":"J Rheumatol"},{"key":"4043_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/0394632015606846","volume":"29","author":"A Cata De","year":"2016","unstructured":"De Cata A, Inglese M, Molinaro F, De Cosmo S, Rubino R, Bernal M et al (2016) Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol 29:180\u2013187","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4043_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3899\/jrheum.131284","volume":"41","author":"M Cutolo","year":"2014","unstructured":"Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, Paolino S, Seriolo B, Cimmino M, Sulli A (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 41:881\u2013886","journal-title":"J Rheumatol"},{"issue":"1","key":"4043_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/14397595.2016.1192761","volume":"27","author":"V Cestelli","year":"2017","unstructured":"Cestelli V, Manfredi A, Sebastiani M, Praino E, Cannarile F, Giuggioli D, Ferri C (2017) Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis. Mod Rheumatol 27(1):110\u2013114","journal-title":"Mod Rheumatol"},{"key":"4043_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2172-11-62","volume":"11","author":"P D\u2019Amelio","year":"2010","unstructured":"D\u2019Amelio P, Cristofaro MA, D\u2019Amico L, Veneziano L, Roato L, Sassi F (2010) Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 11:62\u201368","journal-title":"BMC Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4043-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T19:36:31Z","timestamp":1550777791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4043-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4043-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"4 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective study was approved by the Ethical Committee (protocol n. 282\/15). All patients gave their written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}